Results of the Lilly-funded study provide a promising first look. Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat obesity and diabetes. By Rebecca Robbins and Gina Kolata Encouraging ...

What a difference five years can make. Just look at Eli Lilly (NYSE: LLY). In April 2020, the drugmaker stood in the shadows to some extent with companies including Johnson & Johnson, Pfizer ...

Eli Lilly announced a successful Phase 3 clinical trial of its new GLP-1 weight loss drug, orforglipron, which comes in pill form -- not an injection. This first trial showed weight loss of 7.9% ...

Eli Lilly & Co. shares surged after its experimental pill helped patients shed weight and control blood sugar about as well as Ozempic, an advance that could turbocharge what’s already one of ...

Eli Lilly & Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer to developing a needle-free alternative to injections.

Eli Lilly's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain dosages and lowered blood sugar in patients during a clinical trial.

From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%. Last year was a transformative year for the Indianapolis-based pharmaceutical giant ...

Eli Lilly, for its part, sells tirzepatide as Mounjaro and Zepbound for diabetes and obesity, respectively. In addition, retatrutide is Lilly’s next-generation weight loss candidate.

Ore Huiying / Bloomberg / Getty Images Shares of Eli Lilly jumped 16% Thursday morning after the pharmaceutical company released Phase 3 trial results for its oral weight-loss drug that ...

Orforglipron, an experimental treatment Eli Lilly is developing for diabetes and weight loss, hit high marks in the first of several pivotal trials. The daily tablet produced blood-sugar ...

Eli Lilly shares jumped 15% after a clinical trial of its experimental pill showed it helped patients with Type 2 diabetes lose weight at levels comparable to leading injectable medications like ...